Carl Whatley leads Vitruvias with expert knowledge of all facets of the generic pharmaceutical drug industry. His leadership background coupled with a passion to expand the generic drug market have led to the development of multiple successful companies bringing next generation drugs into American pharmacies.
Bryce Harvey leads Vitruvias as Vice Manager, Co-Founder and Director. With decades of experience at Johnson & Johnson and successful growth of two companies prior to Vitruvias, Bryce is a seasoned industry leader with an acute sense for business development and key partnerships.
Michael Altman joined Perceptive in 2007 and is a senior analyst on the investment team. His focus is on medical devices, diagnostics,digital health and Specialty Pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration. Michael serves on the board of directors for Vensun Pharmaceuticals and Vitruvias Therapeutics.
Mr. Schutter is a seasoned executive with over 30 years of experience in the pharmaceutical industry. Mr. Schutter is currently President and Chief Executive Officer of Arbor Pharmaceuticals, a specialty pharmaceutical company focused on the cardiovascular, hospital, and pediatric markets as well as generics through its Wilshire division. He also serves on the board of directors at Arbor. Prior to joining Arbor, Mr. Schutter served as President and Chief Operating Officer of Sciele (Shionogi) Pharmaceuticals. Prior to Sciele, he served as VP of Global Business Development at Solvay Pharmaceuticals based in Basel, Switzerland. Mr. Schutter also held several senior management roles in commercial operations at the U.S. subsidiary of Solvay during his twenty years with the organization. He began his pharmaceutical career with Reid-Provident Labs, a small entrepreneurial pharmaceutical company based in Atlanta, Ga. Mr. Schutter has a BS in Pharmacy from Mercer University and an MBA from Kennesaw State University.
Jason Wild is the President and Chief Investment Officer of JW Asset Management, LLC, the advisor for three investment partnerships. Mr. Wild received his license as a pharmacist in 1997,and subsequently founded JW Asset Management, LLC in 1998. The firm has a strong history of finding opportunities within the specialty pharmaceutical sector. Mr. Wild currently serves as Chairman of the Board at Arbor Pharmaceuticals, Inc. He is a graduate of the Arnold and Marie Schwartz College of Pharmacy where he received a bachelor’s degree in Pharmacy.